The Imaging Response Assessment Team (IRAT) is a shared resource providing image-based tumor metrics for cancer research, as one of a national consortium of cancer center IRATs. The IRAT serves as a key component of investigator-initiated, cooperative group and industry-sponsored clinical trials at Moffitt, providing quantitative size-based measurements of tumor response. Year-to-year increases in the volume of service have generated the need for a cost center to support and institutionalize the Moffitt IRAT. The present proposal seeks to expand the capabilities and scope of this IRAT to support the infrastructure necessary for investigator-initiated studies at Moffitt.
The specific aims for the current effort are to support the IRAT infrastructure, which is used to: 1) Maintain the current quality of reported quantitative data and rapid response time;2) Expand the quantitative nature of reporting through more detailed image analysis;3) Coordinate acquisition and analysis of radiological images in support of clinical trials;4) Consult in clinical trials protocol submission;5) Review clinical trials in Scientific Review Committee;6) Provide pilot data for grant submissions;7) Assist in development of non-traditional imaging endpoints for response assessment, including participation in ACRIN and COG trials;and 8) Educate and reach out to Moffitt oncologists and investigators to increase awareness of new horizons in cancer imaging. These achievements are critical to accommodate the increasing complexity and importance of imaging biomarkers in response assessment, as the limitations and inadequacies of conventional metrics are recognized. An expansion of IRAT personnel is an immediate need to realize these goals. In 2009, 169 clinical trials with a primary imaging endpoint to assess tumor response were active, with the majority originating from the Experimental Therapeutics program, followed by Immunology. Of these, 71 were investigator-initiated, non-Industrial Moffitt or cooperative trials, and 94 had new patient accrual in 2009. These clinical trials spanned the breadth of Oncology Groups at Moffitt. The Core requests CCSG support of $153,973 which is 39% of its operational budget.

Public Health Relevance

The IRAT adds value to the CC mission by streamlining the process of integrating imaging into trials and providing QA/QC throughout the process, especially for trials not initiated by radiologists. Developing an infrastructure for the IRAT has permitted the pursuit of other funded trial opportunities that use advanced and/or investigational imaging techniques, analysis, and novel biomarkers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-16
Application #
8613460
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$65,400
Indirect Cost
$26,587
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Porubsky, Caitlin; Teer, Jamie K; Zhang, Yonghong et al. (2018) Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus. J Cutan Pathol 45:180-183
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Huang, Qingling; Chen, Lihong; Yang, Leixiang et al. (2018) MDMX acidic domain inhibits p53 DNA binding in vivo and regulates tumorigenesis. Proc Natl Acad Sci U S A 115:E3368-E3377
Li, Yafang; Xiao, Xiangjun; Han, Younghun et al. (2018) Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis 39:336-346
Zhu, Genyuan; Nemoto, Satoshi; Mailloux, Adam W et al. (2018) Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol 9:1609
Karolak, Aleksandra; Markov, Dmitry A; McCawley, Lisa J et al. (2018) Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues. J R Soc Interface 15:
Liu, Ying; Wang, Hua; Li, Qian et al. (2018) Radiologic Features of Small Pulmonary Nodules and Lung Cancer Risk in the National Lung Screening Trial: A Nested Case-Control Study. Radiology 286:298-306
Padron, Eric; Ball, Markus C; Teer, Jamie K et al. (2018) Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood 131:2402-2405
Verduzco, Daniel; Kuenzi, Brent M; Kinose, Fumi et al. (2018) Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. Mol Cancer Ther 17:73-83

Showing the most recent 10 out of 1254 publications